Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan

Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days

Veristat expands global trial & regulatory services as Chinese drugmakers push overseas

The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

Marks significant milestone for breakthrough biologic to treat rare blood cancers

Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis

The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab

India tackles rare diseases head-on at landmark summit in New Delhi

Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration

NewcelX and Eledon join forces to advance potential Type 1 diabetes cure

The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets

EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients

The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation

Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors

Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile